ReviewCureus2026
Neuro-Oncology Biotech Industry Progress Report 2025.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuro-oncology is central to the rapidly expanding field of cancer therapeutics, with surges in clinical trials exploring innovative treatment strategies. The 2025 Brain Tumor Biotech Summit was hosted by Northwell Health Lenox Hill Hospital's Department of Neurosurgery, the Feinstein Institute for Medical Research, and the Zucker School of Medicine in New York City in June 2025. The summit highlighted recent advancements in neuro-oncology, with a focus on emerging treatments, novel drug delivery platforms, and device-based therapeutics. Leaders from academia, biotechnology, and investment communities presented progress on clinical trials, early-phase technologies, and personalized treatment strategies for glioblastoma (GBM) and other CNS tumors. This report summarizes the key discussions at the summit and emphasizes the importance of translational partnerships in accelerating therapy development for glioma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.